APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard...

APP Pharmaceuticals Names Thomas H. Silberg Chief Executive Officer; Appoints Richard J. Tajak Chief Financial Officer

SCHAUMBURG, Ill.--(Business Wire)--
APP Pharmaceuticals, Inc. (Nasdaq:APPX), a leading manufacturer of
multi-source and branded injectable pharmaceutical products, today
announced that Thomas H. Silberg has been promoted to president and
chief executive officer, succeeding Patrick Soon-Shoing, M.D., who
will remain as chairman of the board. The company also announced that
Richard J. Tajak has been appointed executive vice president and chief
financial officer, succeeding Lisa Gopala. Both Patrick and Lisa
served in their roles under a shared services arrangement following
the separation of APP and Abraxis BioScience in November 2007. These
two appointments are consistent with representations made to the
Internal Revenue Service in connection with the receipt of the private
letter ruling in the separation.

Mr. Silberg, 61, has served as APP's president since November
2007. Earlier, he served as president of Abraxis Pharmaceutical
Products (the division name of APP prior to the separation). Mr.
Silberg joined APP in May 2006 as executive vice president, commercial
operations and operational excellence and was responsible for the
commercial operations of APP. Earlier, he served as chief operating
officer of Tercica, Inc., where his direct responsibilities included
regulatory, clinical development, medical affairs, manufacturing,
quality assurance/quality control, sales and marketing, business
development, and project management. Before that, he was executive
vice president and chief operating officer of Ligand Pharmaceuticals
after serving as senior vice president of commercial operations. Mr.
Silberg began his career in 1972 with Hoffmann-LaRoche, Inc., where he
rose through the management ranks to vice president of business
operations.

Mr. Tajak, 55, joined APP in March 2008 as the company's senior
vice president, finance. He has over 20 years of broad and extensive
pharmaceutical experience, serving most recently as Sr. Vice
President, Finance for the North American operations of Astellas
Pharmaceuticals, Inc. Earlier, he held senior management positions at
Fujisawa Healthcare/USA and before that at Lyphomed, Inc. Mr. Tajak is
a certified public accountant (CPA). He earned a bachelors degree in
finance and a masters of business administration degree from the
University of Notre Dame.

"Tom is eminently qualified to lead APP and his experience with
the company ensures a smooth transition," said Patrick Soon Shiong.
"Rich's deep and broad expertise in finance, includes corporate and
managerial accounting, strategic planning and analysis, treasury,
taxation and corporate operations. Both executives have a diverse
skill set and bring a wealth of pharmaceutical industry experience to
their new roles at APP."

About APP Pharmaceuticals

APP is a specialty drug company that develops, manufactures and
markets injectable pharmaceutical products, focusing on oncology,
anti-infective, anesthetic/analgesic and critical care markets. The
company is one of the largest producers of injectables, with more than
100 products in more than 400 dosage formulations. APP, headquartered
in Schaumburg, Illinois, has offices in Canada and manufacturing
operations in Illinois, New York and Puerto Rico and is traded on the
Nasdaq Global Market under the symbol APPX. For more information about
APP and the products it provides, please visit www.APPpharma.com.

Investors and Media Inquiries:
APP Pharmaceuticals, Inc.
Maili Bergman, Director, Investor Relations, 310-405-7522
or
PondelWilkinson Inc.
Robert Jaffe, 310-279-5969

Copyright Business Wire 2008